Acute, severe Pain

Also known as: Severe Acute pain / Acute Severe Pain

DrugDrug NameDrug Description
DB00465KetorolacKetorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet and as an injectable. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis [F3952].
DB00497OxycodoneOxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.
DB00708SufentanilSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments [L4717]. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718]. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 [L4717]. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural administration [L4717], [A39633].
DB06204TapentadolOpioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008.
DrugDrug NamePhaseStatusCount